Dihydromyricetin attenuates fibrosis-associated features of hypertrophic scar with accompanying changes in PI3K/AKT/mTOR-related signaling.

Cao P, Shi A, Wang Y, Hui S, Lyu G · 2026 · Frontiers in Pharmacology · Atlas ID CAO2026B

What this study shows

Dihydromyricetin reduced collagen I/III and α-SMA in hypertrophic scar fibroblasts and improved scar elevation in a rabbit ear model, with accompanying reductions in AKT and mTOR phosphorylation; causality was not established.

Abstract

ShowHide

This study investigated whether dihydromyricetin (DHM) attenuates fibrosis-associated features in hypertrophic scar (HS) and whether these effects are accompanied by changes in PI3K/AKT/mTOR-related signalling. Network pharmacology identified overlapping targets between DHM and HS, highlighting AKT1 as a candidate hub target; molecular docking and 50-ns molecular dynamics simulation indicated a stable predicted DHM-AKT1 interaction.

Read the full abstract on PubMed →

At a glance

Evidence type	A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Rabbit ear hypertrophic scar model; human hypertrophic scar fibroblasts); the code names the system studied -- animal work can be rigorous and still not be human data.
Study type	4 - Animal Study
Model system	Rabbit ear hypertrophic scar model; human hypertrophic scar fibroblasts
Journal	Frontiers in Pharmacology
Year	2026
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.3389/fphar.2026.1862651 · PMID 42656474 · Free full text (PMC13506778)

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	Dihydromyricetin; LY294002 (PI3K inhibitor)
Target	PI3K/AKT/mTOR; AKT1
Model	Rabbit; human fibroblasts
Effect	Reduced fibrotic marker expression and scar elevation index; decreased AKT and mTOR phosphorylation

In the Atlas

Cite this paper

ShowHide

Cao, P., Shi, A., Wang, Y., Hui, S., & Lyu, G. (2026). Dihydromyricetin attenuates fibrosis-associated features of hypertrophic scar with accompanying changes in PI3K/AKT/mTOR-related signaling. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1862651

@article{CAO2026B,
  author       = {Cao, P. and Shi, A. and Wang, Y. and Hui, S. and Lyu, G.},
  title        = {{Dihydromyricetin attenuates fibrosis-associated features of hypertrophic scar with accompanying changes in PI3K/AKT/mTOR-related signaling}},
  journal      = {Frontiers in Pharmacology},
  year         = {2026},
  doi          = {10.3389/fphar.2026.1862651},
  note         = {PMID: 42656474},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record CAO2026B) [Data set]. https://mtor-atlas.org/study/CAO2026B/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_CAO2026B,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record CAO2026B},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/CAO2026B/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?